JP2023519261A5 - - Google Patents

Info

Publication number
JP2023519261A5
JP2023519261A5 JP2022557789A JP2022557789A JP2023519261A5 JP 2023519261 A5 JP2023519261 A5 JP 2023519261A5 JP 2022557789 A JP2022557789 A JP 2022557789A JP 2022557789 A JP2022557789 A JP 2022557789A JP 2023519261 A5 JP2023519261 A5 JP 2023519261A5
Authority
JP
Japan
Prior art keywords
groups
antibody
cancer
pharmaceutically acceptable
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519261A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/082857 external-priority patent/WO2021190583A1/zh
Publication of JP2023519261A publication Critical patent/JP2023519261A/ja
Publication of JP2023519261A5 publication Critical patent/JP2023519261A5/ja
Pending legal-status Critical Current

Links

JP2022557789A 2020-03-25 2021-03-25 抗psma抗体-エキサテカン類似体複合体及びその医薬用途 Pending JP2023519261A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010218297 2020-03-25
CN202010218297.4 2020-03-25
PCT/CN2021/082857 WO2021190583A1 (zh) 2020-03-25 2021-03-25 抗psma抗体-依喜替康类似物偶联物及其医药用途

Publications (2)

Publication Number Publication Date
JP2023519261A JP2023519261A (ja) 2023-05-10
JP2023519261A5 true JP2023519261A5 (enExample) 2024-04-02

Family

ID=77890968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557789A Pending JP2023519261A (ja) 2020-03-25 2021-03-25 抗psma抗体-エキサテカン類似体複合体及びその医薬用途

Country Status (12)

Country Link
US (1) US20230140397A1 (enExample)
EP (1) EP4130006A4 (enExample)
JP (1) JP2023519261A (enExample)
KR (1) KR20220160016A (enExample)
CN (1) CN115298186B (enExample)
AU (1) AU2021240756A1 (enExample)
BR (1) BR112022019027A2 (enExample)
CA (1) CA3177279A1 (enExample)
MX (1) MX2022011808A (enExample)
TW (1) TWI888517B (enExample)
WO (1) WO2021190583A1 (enExample)
ZA (1) ZA202210724B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
KR20260040624A (ko) * 2023-07-25 2026-03-25 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 c-Met를 표적으로 하는 항체-약물 접합체 및 이의 의학적 용도
WO2025031285A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 抗psma抗体-药物偶联物及其医药用途
TW202542201A (zh) * 2023-12-29 2025-11-01 瑞士商T O A D 腫瘤學股份有限公司 抗psma軛合物及其使用方法
WO2026138778A1 (zh) * 2024-12-23 2026-07-02 江苏恒瑞医药股份有限公司 一种包含抗c-Met抗体-药物偶联物的药物组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
AU2006262231B2 (en) * 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス, インコーポレイテッド 非全身性tgr5アゴニスト
CN104168899B (zh) 2012-01-13 2017-04-05 通用医疗公司 麻醉剂化合物及其相关的使用方法
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
WO2015012904A2 (en) * 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US11185594B2 (en) * 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
PL3204018T3 (pl) * 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
US10195175B2 (en) * 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017046746A1 (en) * 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CN117534764A (zh) * 2016-06-06 2024-02-09 阿布泽纳(英国)有限公司 抗体、其用途及其缀合物
CN112469440B (zh) * 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
UA130338C2 (uk) * 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物

Similar Documents

Publication Publication Date Title
JP2023510905A5 (enExample)
JP2023505708A5 (enExample)
JP2022511351A5 (enExample)
JP2023506805A5 (enExample)
TWI891749B (zh) 抗體-藥物偶聯物及其醫藥用途
CA2933666C (en) Anti-trop2 antibody-drug conjugate
JP2023535598A5 (enExample)
CN107148285B (zh) 吡咯并苯并二氮杂䓬-抗体缀合物
WO2015146132A1 (ja) 抗cd98抗体-薬物コンジュゲート
JP2017534253A5 (enExample)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2015523380A5 (enExample)
TW202537975A (zh) 抗體-藥物結合物之製造方法
TW202227501A (zh) 抗garp抗體及其製造方法及用途
CN116096896A (zh) 一种含抗体药物偶联物的药物组合物及其用途
JP2020504112A5 (enExample)
AU2018328015A1 (en) Compounds for reducing the viscosity of biological formulations
CA3243873A1 (en) Immune Antigen-Specific IL-18 Immune Cytokines and Their Uses
JP2024523422A5 (enExample)
JP2025503493A5 (enExample)
NL2020121B1 (en) Platinum-based functional moieties for preparing cell targeting conjugates
JP2024536798A5 (enExample)
RU2022125170A (ru) Конъюгат антитела против PSMA и аналога эксатекана и его медицинское применение
JP2025516775A (ja) 新規なマスクされた抗体
TH2101001650A (th) ลิแกนด์-ดรักคอนจูเกตของสารแอนะล็อกของเอกซาทีแคน, วิธีการเตรียมสำหรับคอนจูเกตนั้น และการประยุกต์ใช้คอนจูเกตดังกล่าว